Affimed (NASDAQ:AFMD – Get Rating) – Investment analysts at Truist Financial issued their Q1 2022 earnings per share (EPS) estimates for Affimed in a research note issued on Monday, April 4th. Truist Financial analyst S. Devarakonda forecasts that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter. Truist Financial also issued estimates for Affimed’s Q2 2022 earnings at ($0.25) EPS, Q3 2022 earnings at ($0.24) EPS, Q4 2022 earnings at ($0.27) EPS and FY2026 earnings at $0.30 EPS. Affimed (NASDAQ:AFMD – Get Rating) last announced its earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Affimed had a negative net margin of 149.76% and a negative return on equity of 40.66%. During the same period in the previous year, the business posted ($0.20) earnings per share.
Other analysts have also issued research reports about the company. Zacks Investment Research raised Affimed from a “sell” rating to a “hold” rating in a research report on Wednesday, March 30th. Cantor Fitzgerald initiated coverage on shares of Affimed in a research note on Wednesday, February 23rd. They issued an “overweight” rating and a $12.00 price target for the company. StockNews.com downgraded shares of Affimed from a “hold” rating to a “sell” rating in a research note on Monday, March 28th. SVB Leerink restated a “buy” rating on shares of Affimed in a research note on Sunday, December 12th. Finally, Piper Sandler initiated coverage on shares of Affimed in a research note on Wednesday, March 30th. They issued an “overweight” rating and a $7.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $10.86.
Shares of NASDAQ AFMD opened at $4.86 on Tuesday. The firm has a market cap of $477.69 million, a price-to-earnings ratio of -8.53 and a beta of 2.53. The company has a quick ratio of 3.19, a current ratio of 3.20 and a debt-to-equity ratio of 0.13. Affimed has a 52-week low of $3.59 and a 52-week high of $11.74. The business’s 50 day moving average is $4.28 and its two-hundred day moving average is $5.33.
Several hedge funds have recently modified their holdings of AFMD. BlackRock Inc. boosted its stake in Affimed by 1.0% in the fourth quarter. BlackRock Inc. now owns 6,848,983 shares of the biopharmaceutical company’s stock valued at $37,805,000 after acquiring an additional 70,893 shares in the last quarter. Deutsche Bank AG boosted its stake in Affimed by 2.2% in the fourth quarter. Deutsche Bank AG now owns 208,115 shares of the biopharmaceutical company’s stock valued at $1,149,000 after acquiring an additional 4,386 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Affimed by 7.5% in the fourth quarter. Parametric Portfolio Associates LLC now owns 200,631 shares of the biopharmaceutical company’s stock valued at $1,107,000 after acquiring an additional 13,916 shares in the last quarter. Kennedy Capital Management Inc. acquired a new position in Affimed in the fourth quarter valued at $445,000. Finally, Centiva Capital LP acquired a new position in Affimed in the fourth quarter valued at $102,000. Hedge funds and other institutional investors own 69.91% of the company’s stock.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL.